Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$5.97.

  • Spyre Therapeutics' EPS (Basic) rose 8586.65% to -$5.97 in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.07, marking a year-over-year increase of 8771.15%. This contributed to the annual value of -$4.42 for FY2024, which is 9919.62% up from last year.
  • Spyre Therapeutics' EPS (Basic) amounted to -$5.97 in Q3 2025, which was up 8586.65% from -$19.62 recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' EPS (Basic) ranged from a high of $40.14 in Q2 2023 and a low of -$564.94 during Q4 2023
  • Its 5-year average for EPS (Basic) is -$37.34, with a median of -$4.84 in 2022.
  • Within the past 5 years, the most significant YoY rise in Spyre Therapeutics' EPS (Basic) was 1496666.67% (2023), while the steepest drop was 1194562.9% (2023).
  • Quarter analysis of 5 years shows Spyre Therapeutics' EPS (Basic) stood at -$24.33 in 2021, then soared by 80.72% to -$4.69 in 2022, then tumbled by 11945.63% to -$564.94 in 2023, then soared by 99.79% to -$1.2 in 2024, then tumbled by 398.71% to -$5.97 in 2025.
  • Its EPS (Basic) was -$5.97 in Q3 2025, compared to -$19.62 in Q2 2025 and -$23.95 in Q1 2025.